These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33341408)

  • 1. Exon identity influences splicing induced by exonic variants and in silico prediction efficacy.
    Martin N; Bergougnoux A; Baatallah N; Chevalier B; Varilh J; Baux D; Costes B; Fanen P; Raynal C; Sermet-Gaudelus I; Girodon E; Taulan-Cadars M; Hinzpeter A
    J Cyst Fibros; 2021 May; 20(3):464-472. PubMed ID: 33341408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined computational-experimental analyses of CFTR exon strength uncover predictability of exon-skipping level.
    Aissat A; de Becdelièvre A; Golmard L; Vasseur C; Costa C; Chaoui A; Martin N; Costes B; Goossens M; Girodon E; Fanen P; Hinzpeter A
    Hum Mutat; 2013 Jun; 34(6):873-81. PubMed ID: 23420618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical 5' splice sites cause CFTR exon 9 to be vulnerable to skipping.
    Hefferon TW; Broackes-Carter FC; Harris A; Cutting GR
    Am J Hum Genet; 2002 Aug; 71(2):294-303. PubMed ID: 12068373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multi-faceted nature of 15 CFTR exonic variations: Impact on their functional classification and perspectives for therapy.
    Bergougnoux A; Billet A; Ka C; Heller M; Degrugillier F; Vuillaume ML; Thoreau V; Sasorith S; Bareil C; Thèze C; Ferec C; Gac GL; Bienvenu T; Bieth E; Gaston V; Lalau G; Pagin A; Malinge MC; Dufernez F; Lemonnier L; Koenig M; Fergelot P; Claustres M; Taulan-Cadars M; Kitzis A; Reboul MP; Becq F; Fanen P; Mekki C; Audrezet MP; Girodon E; Raynal C
    J Cyst Fibros; 2023 May; 22(3):515-524. PubMed ID: 36567205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element.
    Pagani F; Buratti E; Stuani C; Romano M; Zuccato E; Niksic M; Giglio L; Faraguna D; Baralle FE
    J Biol Chem; 2000 Jul; 275(28):21041-7. PubMed ID: 10766763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular diagnosis of cystic fibrosis by RNA obtained from nasal epithelial cells.
    Prior-de Castro C; Martínez Gallego MÁ; Gómez-González C; de Sancho Martín R; Rodríguez-Antolín C; Rodríguez-Jiménez C; Del Pozo Mate Á; Zamarrón de Lucas E; Ruiz de Valbuena Maiz M; de Manuel Gómez C; Alcolea Batres S; Prados Sánchez MC; J Torres R
    J Cyst Fibros; 2024 Jul; 23(4):788-795. PubMed ID: 38151412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles.
    Steiner B; Truninger K; Sanz J; Schaller A; Gallati S
    Hum Mutat; 2004 Aug; 24(2):120-9. PubMed ID: 15241793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis.
    Masvidal L; Igreja S; Ramos MD; Alvarez A; de Gracia J; Ramalho A; Amaral MD; Larriba S; Casals T
    Eur J Hum Genet; 2014 Jun; 22(6):784-91. PubMed ID: 24129438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rescue of common exon-skipping mutations in cystic fibrosis with modified U1 snRNAs.
    Donegà S; Rogalska ME; Pianigiani G; Igreja S; Amaral MD; Pagani F
    Hum Mutat; 2020 Dec; 41(12):2143-2154. PubMed ID: 32935393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter architecture modulates CFTR exon 9 skipping.
    Pagani F; Stuani C; Zuccato E; Kornblihtt AR; Baralle FE
    J Biol Chem; 2003 Jan; 278(3):1511-7. PubMed ID: 12421814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies.
    Joynt AT; Evans TA; Pellicore MJ; Davis-Marcisak EF; Aksit MA; Eastman AC; Patel SU; Paul KC; Osorio DL; Bowling AD; Cotton CU; Raraigh KS; West NE; Merlo CA; Cutting GR; Sharma N
    PLoS Genet; 2020 Oct; 16(10):e1009100. PubMed ID: 33085659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene.
    Aznarez I; Chan EM; Zielenski J; Blencowe BJ; Tsui LC
    Hum Mol Genet; 2003 Aug; 12(16):2031-40. PubMed ID: 12913074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of a Cystic Fibrosis Splicing Mutation by Antisense Oligonucleotides.
    Igreja S; Clarke LA; Botelho HM; Marques L; Amaral MD
    Hum Mutat; 2016 Feb; 37(2):209-15. PubMed ID: 26553470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations.
    Nissim-Rafinia M; Chiba-Falek O; Sharon G; Boss A; Kerem B
    Hum Mol Genet; 2000 Jul; 9(12):1771-8. PubMed ID: 10915765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X.
    Aznarez I; Zielenski J; Rommens JM; Blencowe BJ; Tsui LC
    J Med Genet; 2007 May; 44(5):341-6. PubMed ID: 17475917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental assessment of splicing variants using expression minigenes and comparison with in silico predictions.
    Sharma N; Sosnay PR; Ramalho AS; Douville C; Franca A; Gottschalk LB; Park J; Lee M; Vecchio-Pagan B; Raraigh KS; Amaral MD; Karchin R; Cutting GR
    Hum Mutat; 2014 Oct; 35(10):1249-59. PubMed ID: 25066652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of CFTR intronic variants identified during cystic fibrosis population screening by a minigene splicing assay.
    Giorgi G; Casarin A; Trevisson E; Donà M; Cassina M; Graziano C; Picci L; Clementi M; Salviati L
    Clin Chem Lab Med; 2015 Oct; 53(11):1719-23. PubMed ID: 25781545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects.
    Fernandez Alanis E; Pinotti M; Dal Mas A; Balestra D; Cavallari N; Rogalska ME; Bernardi F; Pagani F
    Hum Mol Genet; 2012 Jun; 21(11):2389-98. PubMed ID: 22362925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal mRNA splicing resulting from three different mutations in the CFTR gene.
    Hull J; Shackleton S; Harris A
    Hum Mol Genet; 1993 Jun; 2(6):689-92. PubMed ID: 7689009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.